EA032977B1 - Генетически стабильный онколитический рнк вирус, способ его производства и применения - Google Patents

Генетически стабильный онколитический рнк вирус, способ его производства и применения

Info

Publication number
EA032977B1
EA032977B1 EA201690232A EA201690232A EA032977B1 EA 032977 B1 EA032977 B1 EA 032977B1 EA 201690232 A EA201690232 A EA 201690232A EA 201690232 A EA201690232 A EA 201690232A EA 032977 B1 EA032977 B1 EA 032977B1
Authority
EA
Eurasian Patent Office
Prior art keywords
virus
human
manufacture
rna virus
modified
Prior art date
Application number
EA201690232A
Other languages
English (en)
Other versions
EA201690232A1 (ru
Inventor
Дите Венскус
Иварс Калвиньш
Даце Пьянова
Рамона Петровска
Юргис Аузиньш
Original Assignee
Дитесан Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дитесан Лтд. filed Critical Дитесан Лтд.
Publication of EA201690232A1 publication Critical patent/EA201690232A1/ru
Publication of EA032977B1 publication Critical patent/EA032977B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В способе производства модифицированного энтеровируса ECHO 7 типа посредством модификации природного ECHO 7 вируса, выделенного известным способом из фекалий человека и идентифицированного по последовательности генома, модификацию осуществляли изначально путем проведения адаптации вируса в раковых клетках, ослабленных противоопухолевым средством дакарбазином, затем пассировали модифицированный вирус в культуре эмбриональных фибробластов человека с последующим репродуцированием в клетках меланомы человека и дальнейшим пассированием в культуре эмбриональных фибробластов человека, затем обрабатывали рибавирином, выделяли и очищали известным способом. Модифицированный вирус является пригодным в лечении ряда опухолей.
EA201690232A 2013-07-16 2014-07-16 Генетически стабильный онколитический рнк вирус, способ его производства и применения EA032977B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13176757.6A EP2826856B9 (en) 2013-07-16 2013-07-16 Genetically stable oncolytic RNA virus, method of manufacturing and use thereof
PCT/EP2014/065277 WO2015007788A1 (en) 2013-07-16 2014-07-16 Genetically stable oncolytic rna virus, method of manufacturing and use thereof

Publications (2)

Publication Number Publication Date
EA201690232A1 EA201690232A1 (ru) 2016-05-31
EA032977B1 true EA032977B1 (ru) 2019-08-30

Family

ID=48790285

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690232A EA032977B1 (ru) 2013-07-16 2014-07-16 Генетически стабильный онколитический рнк вирус, способ его производства и применения

Country Status (16)

Country Link
US (2) US10174291B2 (ru)
EP (2) EP2826856B9 (ru)
JP (1) JP6293882B2 (ru)
CN (2) CN105518128B (ru)
AU (1) AU2014292114B2 (ru)
BR (1) BR112016000874B1 (ru)
CA (1) CA2917584C (ru)
EA (1) EA032977B1 (ru)
ES (1) ES2566146T3 (ru)
GE (1) GEP201706763B (ru)
HK (1) HK1219500A1 (ru)
MD (1) MD4480C1 (ru)
MX (1) MX365075B (ru)
PL (2) PL2826856T3 (ru)
UA (1) UA116387C2 (ru)
WO (1) WO2015007788A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109276580B (zh) * 2017-07-21 2021-08-24 厦门大学 一种用于治疗肿瘤的病毒
CN109419818B (zh) * 2017-08-24 2021-08-10 厦门大学 一种用于治疗肿瘤的埃可病毒
CN107669707A (zh) * 2017-11-16 2018-02-09 邹罡 埃可病毒作为溶瘤病毒在抗肿瘤中的应用
CN110064044B (zh) * 2018-01-20 2022-09-09 中国科学院武汉病毒研究所 一种肠道病毒71型的抑制剂及应用
GB201808500D0 (en) 2018-05-23 2018-07-11 Ditesan Ltd Virus and virus use
WO2020035423A1 (en) 2018-08-13 2020-02-20 Ditesan Ltd. Combination therapy of cancer by administrating echo-7 virus and a pharmaceutically effective anti-cancer drug

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1537872A1 (en) * 2002-06-14 2005-06-08 Venskus, Dite Immunostimulator having antineoplastic action and method for producing said immunostimulator

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987101A (en) 1988-12-16 1991-01-22 International Business Machines Corporation Method for providing improved insulation in VLSI and ULSI circuits
CN1244583A (zh) * 1998-08-12 2000-02-16 财团法人生物技术开发中心 本土性猪水泡病病毒与其变异株的制备方法及用途
IL148621A0 (en) * 1999-09-17 2002-09-12 Pro Virus Inc Oncolytic virus
AUPQ425699A0 (en) * 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US6602862B1 (en) * 2000-09-19 2003-08-05 Merz Pharma Gmbh & Co., Kgaa 1-Amino-alkylcyclohexanes as trypanocidal agents
WO2002072027A2 (en) * 2001-03-14 2002-09-19 University Of Alabama Research Foundation Oncolytic rna replicons
AU2002953436A0 (en) * 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
WO2004094454A2 (en) * 2003-04-18 2004-11-04 Idm Pharma, Inc. Hla-a2 tumor associated antigen peptides and compositions
CN101132798B (zh) * 2005-01-17 2011-04-27 溶瘤病毒有限公司 核酸分子在制备用于治疗黑色素瘤的药物中的应用及其组合物
JP5448840B2 (ja) * 2006-12-22 2014-03-19 プシオクサス・セラピューティクス・リミテッド 腫瘍退縮アデノウイルスの作出およびその使用
WO2010009735A2 (en) * 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
CA2689707A1 (en) * 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1537872A1 (en) * 2002-06-14 2005-06-08 Venskus, Dite Immunostimulator having antineoplastic action and method for producing said immunostimulator

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHUA B H, MCMINN P C, LAM S K, CHUA K B: "Comparison of the complete nucleotide sequences of echovirus 7 strain UMMC", JOURNAL OF GENERAL VIROLOGY., SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD., GB, vol. 82, no. 11, 1 November 2001 (2001-11-01), GB, pages 2629 - 2639, XP002717948, ISSN: 0022-1317, DOI: 10.1099/0022-1317-82-11-2629 *
FERDAT A K,: "IMMUNOMODULATION MECHANICS IN THE ANTI-TUMOUR EFFECT OF THE ECHO-7 ENTEROVIRUS", EKSPERIMENTAL NAA ONKOLOGIA - EXPERIMENTAL ONCOLOGY., KIEV, UU, vol. 11, no. 05, 1 January 1989 (1989-01-01), UU, pages 43 - 48, XP008054566, ISSN: 0204-3564 *

Also Published As

Publication number Publication date
EA201690232A1 (ru) 2016-05-31
MD20160014A2 (ru) 2016-07-31
MX2016000462A (es) 2016-07-26
PL2826856T3 (pl) 2016-06-30
AU2014292114B2 (en) 2018-12-20
US20160376562A1 (en) 2016-12-29
EP3022297B1 (en) 2023-07-05
EP2826856B1 (en) 2015-12-23
CN105518128A (zh) 2016-04-20
EP3022297A1 (en) 2016-05-25
US10435672B2 (en) 2019-10-08
US20190144833A1 (en) 2019-05-16
MX365075B (es) 2019-05-22
EP2826856B9 (en) 2016-05-04
HK1219500A1 (zh) 2017-04-07
WO2015007788A1 (en) 2015-01-22
PL3022297T3 (pl) 2023-12-18
CN105518128B (zh) 2019-07-09
EP3022297C0 (en) 2023-07-05
AU2014292114A1 (en) 2016-02-18
US10174291B2 (en) 2019-01-08
CN110129284A (zh) 2019-08-16
EP2826856A1 (en) 2015-01-21
CA2917584A1 (en) 2015-01-22
ES2566146T3 (es) 2016-04-11
BR112016000874B1 (pt) 2019-07-16
JP2016529886A (ja) 2016-09-29
BR112016000874A2 (pt) 2017-03-21
UA116387C2 (uk) 2018-03-12
CA2917584C (en) 2018-02-27
MD4480C1 (ru) 2017-12-31
JP6293882B2 (ja) 2018-03-14
MD4480B1 (ru) 2017-05-31
GEP201706763B (en) 2017-10-25

Similar Documents

Publication Publication Date Title
EA032977B1 (ru) Генетически стабильный онколитический рнк вирус, способ его производства и применения
SG10201802982WA (en) Newcastle disease viruses and uses thereof
MX2018010529A (es) Composiciones y metodos para la produccion y administracion de acido ribonucleico.
MY176822A (en) Anti-pd-1 antibody and use thereof
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
EP3372685A3 (en) Cell lines for virus production and methods of use
MX353476B (es) Anticuerpos anti-cxcl13 y metodos para usarlos.
MX2018004600A (es) Celulas aniquiladoras naturales y células ilc3 y usos de las mismas.
MX2015001871A (es) Celulas asesinas naturales y usos de las mismas.
MX371202B (es) Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética.
IN2015DN02826A (ru)
MX342995B (es) Métodos de generar células asesinas naturales.
NZ601325A (en) Compositions and methods for treating glioblastoma gbm
MX2012005782A (es) Procedimientos, composiciones y kits de liofilizacion.
NZ595641A (en) Humanized anti-egfl7 antibodies and methods using same
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
EA201590747A1 (ru) Способы лечения с использованием аденовируса
MX2021009554A (es) Produccion de virus en cultivos celulares.
MX2016005824A (es) Metodo de cultivo celular.
NZ735160A (en) Cell therapeutic agent for cancer treatment and combination therapy with same
EA201891335A1 (ru) Добавление аргинина с целью повышения эффективности ацетогенов, ферментирующих газ
NZ601661A (en) Compositions and methods for treating viral diseases
MX2020005251A (es) Composiciones para mejorar la funcionalidad de células car-t y uso de las mismas.
EA202092991A1 (ru) Модифицированные направляющие рнк, которые используются для редактирования генома
UA51458U (ru) Способ определения жизнеспособности сердечной мышцы в раннем постреанимационном периоде